To address concerns related to the safety profile of both Food and Drug Administration (FDA)–approved and non–FDA-approved intranasal corticosteroid (INCS) use in the adult population.
Data Source
Systematic review of MEDLINE, PubMed, and EMBASE databases using a comprehensive search strategy including all INCS formulations and adverse events. The study design was developed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Additional sources were identified from study references of relevant articles.
Review Methods
A structured literature search was conducted. Each study was graded for level of evidence using the Oxford Centre for Evidence-Based Medicine. Extracted data included population size, study design, drug (dosage, route, and frequency), presence of hypothalamus pituitary axis suppression, ocular symptoms, and treatment-related adverse events.
Results
A total of 60 studies met inclusion criteria. The studies included use of INCS as metered nasal sprays, drops, injections, aerosols, and irrigations. There were no persistent abnormalities in cortisol level or intraocular pressure change. Meta-analysis of epistaxis showed a significantly increased risk in the FDA-approved treatment group in comparison with control (risk ratio 1.56; 95% confidence interval, 1.13-2.14; P = .007).
Conclusions
Overall, it appears that the use of both FDA and published non-FDA application of INCS are safe in the adult population. Meta-analysis demonstrated an increased risk of epistaxis in patients using INCS compared with placebo. Otherwise, there was no significant difference between in adults in the treatment group and placebo group. As an important caveat, the interpretation of safety of nonstandard INCS is restricted to delivery methods and dosages published in the literature.
HigginsJPTAltmanDGSterneJAC, eds. Chapter 8: assessing risk of bias in included studies. In: HigginsJPTGreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated March2011. The Cochrane Collaboration; 2011. www.handbook.cochrane.org
3.
WellsGSheaBO’ConnellJ, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Accessed June 21, 2016. http://www.ohri.ca/ programs/clinical_epidemiology/oxfordasp
4.
ManjiJSinghGOkpalekeC, et al. Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(5):488-493.
5.
ThambooAManjiJSzeitzASantosRD, et al. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014;4(5):397-402.
6.
SmithKAFrenchGMechorBRudmikL.Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(3):228-232.
7.
SoudryEWangJVaezeafsharRKatznelsonLHwangPH.Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016;6(6):568-572.
8.
KimmerleRRollaAR.Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med. 1985;79(4):535-537.
9.
MartinoBJChurchCASeiberlingKA.Effect of intranasal dexamethasone on endogenous cortisol level and intraocular pressure. Int Forum Allergy Rhinol. 2015;5(7):605-609.
10.
FlynnMDBeasleyPTookeJE.Adrenal suppression with intranasal betamethasone drops. J Laryngol Otol. 1992;106(9):827-828.
11.
Bross-SorianoDHanenberg-MilverCSchimelmitz-IdiJ, et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg. 2004;130(2):187-191.
12.
ManLXFarhoodZLuongA, et al. The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients. Int Forum Allergy Rhinol. 2013;3(12):953-957.
13.
SeiberlingKAChangDFNyiradyJParkFChurchCA.Effect of intranasal budesonide irrigations on intraocular pressure. Int Forum Allergy Rhinol. 2013;3(9):704-707.
14.
MossWJKjosKBKarnezisTTLebovitsMJ.Intranasal steroid injections and blindness: our personal experience and a review of the past 60 years. Laryngoscope. 2015;125(4):796-800.
15.
WolfMD.Retinal and choroidal embolization after intranasal injection of triamcinolone acetate. Retina. 2013;33(6):1281-1283.
16.
WeinsteinSFAndrewsCPShahSR, et al. Long-term efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol. Allergy Asthma Proc. 2014;35(4):323-331.
17.
MygindNSørensenHPedersenCB.The nasal mucosa during long-term treatment with beclomethasone dipropionate aerosol: a light-and scanning electron microscopic study of nasal polyps. Acta Otolaryngol. 1978;85(5-6):437-443.
18.
LindqvistNBalleVHKarmaP, et al. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis: a 12-month multicentre study. Allergy. 1986;41(3):179-186.
19.
RatnerPJacobsRMoharD, et al. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105(6):471-479.
20.
BergerWEPrennerBTurnerRMeltzerEO.A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2013;34(6):542-550.
21.
LaForceCJourneayGEMillerSD, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study. Ann Allergy Asthma Immunol. 2013;111(1):45-50.
22.
RosenblutABardinPGMullerB, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007;62(9):1071-1077.
23.
KeithPNieminenJHollingworthKDolovichJ.Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000;30(10):1460-1468.
24.
PenttiläMPoulsenPHollingworthKHolmströmM.Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 microg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy. 2000;30(1):94-102.
25.
MeltzerEOBachertCStaudingerH.Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-1295.
26.
WelchMJBronskyEFindlayS, et al. Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis. Clin Ther. 1994;16(2):253-262.
27.
KlossekJMLalibertéFLalibertéMF, et al. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology. 2001;39(1):17-22.
28.
MeltzerEOShekarTTeperAA.Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011;32(2):159-167.
29.
NayakASSettipaneGAPedinoffA, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute. Ann Allergy Asthma Immunol. 2002;89(3):271-278.
30.
MakiharaSOkanoMFujiwaraT, et al. Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled trial. Allergol Int. 2012;61(2):295-304.
31.
GivenJTCheemaASDreykluftT, et al. Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults. Am J Rhinol Allergy. 2010;24(6):444-450.
32.
JacobsRMartinBHampelF, et al. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin. 2009;25(6):1393-1401.
33.
CourouxPKunjibettuSHallNWingertzahnMA.Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2009;102(1):62-68.
34.
OkuboKNakashimaMMiyakeNKomatsubaraMOkudaM.Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. Allergy Asthma Proc. 2009;30(1):84-94.
35.
OkuboKNakashimaMMiyakeNUchidaJOkudaM.Dose-ranging study of fluticasone furoate nasal spray for Japanese patients with perennial allergic rhinitis*. Curr Med Res Opin. 2008;24(12):3393-3403.
36.
PatelDRatnerPClementsDWuWFarisMPhilpotE.Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol. 2008;100(5):490-496.
37.
AnolikR; Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(3):264-271.
38.
ChervinskyPKunjibettuSMillerDL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007;99(1):69-76.
39.
KaiserHBNaclerioRMGivenJ, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(6):1430-1437.
40.
BendeMCarrilloTVónaIda Castel-BrancoMGArhedenL.A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2002;88(6):617-623.
41.
BerkowitzRBernsteinDLaForceC, et al. Onset of action of mometasone furoate nasal spray(NASONEX(®)) in seasonal allergic rhinitis. Allergy. 1999;54(1):64-69.
42.
DayJCarrilloT.Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 1998;102(6 pt 1):902-908.
43.
MandlMNolopKLutskyBN.Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol. 1997;79(3):237-245.
44.
Newson-SmithGPowellMBaehreMGarnhamSPMacMahonMT.A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol. 1997;254(5):236-241.
45.
HebertJRNolopKLutskyBN.Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy. 1996;51(8):569-576.
46.
DrouinMYangWHBertrandB, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol. 1996;77(2):153-160.
47.
PrennerBMChervinskyPHampelFCJr, et al. Double-strength beclomethasone dipropionate (84 micrograms/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;98(2):302-308.
48.
ClaytonDEKooistraJBGellerM, et al. Short-term efficacy trial and twenty-four-month follow-up of flunisolide nasal spray in the treatment of perennial rhinitis. J Allergy Clin Immunol. 1981;67(1):2-7.
49.
HolmströmM.Clinical performance of fluticasone propionate nasal drops. Allergy. 1999;Suppl 53:21-25.
50.
BrannanMDHerronJMReidenbergPAffrimeMB.Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther. 1995;17(4):637-647.
51.
KnightAKolinA.Long term efficacy and safety of beclomethasone dipropionate aerosol in perennial rhinitis. Ann Allergy. 1983;50(2):81-84.
52.
RaphaelGDBergerWEPrennerBM, et al. Efficacy, safety, and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med Res Opin. 2013;29(10):1329-1340.
53.
GastparHAurichRPetzoldU, et al. Intranasal treatment of perennial allergic rhinitis: comparison of azelastine nasal spray and budesonide nasal aerosol. Arzneimittelforschung. 1993;43(4):475-479.
54.
RatnerPVan BavelJMoharDJacobsRL.Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015;114(2):141-147.
55.
SpectorSBronskyEChervinskyPLotnerG, et al. Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis. Ann Allergy. 1990;64(3):300-305.
56.
MunkZMGrossGNHampelFCJrRatnerPH.Preseasonal, once daily triamcinolone acetonide nasal aerosol for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;78(3):325-331.
57.
RatnerPHPaullBRFindlaySR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol. 1992;90(3 pt 1):285-291.
58.
HowlandWCIIIHampelFCJrMartinBG, et al. The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects. Clin Ther. 1996;18(6):1106-1117.
59.
MeltzerEOBernsteinDIPrennerBMBergerBMShekarT.Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy. 2013;27(2):102-108.
60.
MygindN.Effects of beclomethasone dipropionate aerosol on nasal mucosa. Br J Clin Pharmocol. 1977;4(S3):287S-291S.
61.
BhallaRKPaytonKWrightED.Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of significant adrenal suppression. J Otolaryngol Head Neck Surg. 2008;37(6):821-825.
62.
WelchKCThalerERDoghramjiLLPalmerJNChiuAG.The effects of serum and urinary cortisol levels of topical intranasal irrigations with budesonide added to saline in patient with recurrent polyposis after endoscopic sinus surgery. J Rhinol Allergy. 2010;24(1):26-28.
63.
WeberRGarciaJFaruqiRBanerjiDGeorgesG.Safety and clinical relief over 1 year with triamcinolone acetonide hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2006;27(3):243-247.
64.
ŞimşekABayraktarCDoğanSKarataşMSarıkayaY.The effect of long-term use of intranasal steroids on intraocular pressure. Clin Ophthalmol. 2016;10:1079-1082.
65.
ChongLYHeadKHopkinsC, et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011996.
66.
WuELHarrisWCBabcockCMAlexanderBHRileyCAMcCoulED.Epistaxis risk associated with intranasal corticosteroid sprays: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(1):18-27.
67.
ValenzuelaCVLiuJCVilaPMSimonLDoeringMLieuJEC. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis. Laryngoscope. 2019;129(1):6-12.
68.
LipwothBJSecklJR.Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997;52(5):476-482.
69.
BlaissM.Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2007;28(2):145-152.
70.
ShethKKCookCKPhilpotEE, et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004;25(2):115-120.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
